Contact Info
333 SE 2nd Avenue,
20th Floor Miami, FL
33131 info@breakbio.com

Personalized Immunotherapy

A Breakthrough in the treatment and cure of all solid cancers by attacking 30 unique targets found by AI/ML in each patient.
First in industry: mass spectrometry per patient for AI training.

BREAKBIO'S PATENT-PENDING PERSONALIZED CANCER VACCINE

Cancer vaccines tailor made for each patient

Treatment is in two parts

image

Cancer vaccine to create
T-cells

  • BreakBio AI analyzes cancer cells from each patient to find not one, but many proteins on them
  • AI training repeated per patient from innovative, unique mass spectrometry analysis of each patient's cancer cells
    • Beginning of a new era of AI drug design per patient
  • BreakBio manufactures the drugs: synthetic copies of these proteins, the dawn of personalized drug manufacturing
image

FDA approved cancer drugs for that cancer indication
to help T-cells infiltrate tumors

Reduces barriers to immune system and slows rate of growth of cancer cells

First Trial

BreakBio’s first trial is a phase 1/2 in metastatic colorectal cancer. It will start treating patients in 2024

Died Annually

53200

Colorectal cancer is the second most deadly cancer, after lung cancer, in America.
Late-Stage Chemo Failures May Find Hope In BreakBio's Treatment.
View More
shape

Breakthrough Technology

Our mission is a breakthrough in the treatment and cure of all solid cancers. BreakBio is named for this vision a Breakthrough in Biotech. Our first aim is to quickly achieve Breakthrough Therapy Designation from the FDA for our first cancer indication.

view more
BreakBio’s proprietary

BreakBio’s proprietary, patent-pending AI/ML designed personalized cancer vaccines are for all solid cancers, with the first trial in metastatic colorectal cancer starting in 2024.

Watch Video

BreakBio's Recognition

BreakBio CEO Roy de Souza was honored by the American Cancer Society at an event on May 11, 2023.

Roy de Souza, CEO, Breakbio, shares his story of loss to cancer, and his passion for finding a breakthrough in cancer care.

View More

icon
Designed to benefit both patients with high mutation counts and patients with low mutation counts in their cancer (high or low Tumor Mutational Burden, TMB)

Press Release

Recent Developments and
Press Releases

View All
2024-10-05

BreakBio Selected for Competitive Endless Frontier Labs

View more
2024-04-12

BreakBio Corp receives IND approval from the FDA for BreakVax

View more
Watch video

BreakBio Colon Cancer Vaccine

WHATS NEW

BreakBio article highlights

View All
image

The Gut Truth: Unraveling the Diet-Colon Cancer Connection

Roy de Souza August 28th, 2024
image

FDA "open for business" to review novel cancer vaccines

Admin April 15th, 2024
image

REVOLUTIONIZING CANCER TREATMENT? A CONVERSATION ON THE POTENTIAL OF PERSONALIZED CANCER VACCINES

Prema Pinto March 21st, 2024